Coherus Biosciences, INC Schedule 13G passive stakes

Timothy G. Youngquist 2020 Irrevocable Trust reports 8.3% stake in Coherus Oncology, Inc. as of March 31, 2026.

The Timothy G. Youngquist 2020 Irrevocable Trust has reported beneficial ownership of 8.267% of Coherus Oncology, Inc. common stock.

Thomas A. Satterfield, Jr. filed a Schedule 13G reporting a 4.6% beneficial ownership stake in Coherus Oncology, Inc.

The Vanguard Group reports 0% beneficial ownership of Coherus Oncology Inc. common stock following an internal corporate realignment.

The Timothy G. Youngquist 2020 Irrevocable Trust has reported a 6.49% beneficial ownership stake in Coherus Oncology, Inc., primarily for investment purposes.

The Vanguard Group has reported an 8.29% beneficial ownership stake in Coherus Oncology Inc., holding over 10 million shares as of December 31, 2025.

Bering Partners II, L.P., Bering Partners III, L.P., and their managing members, Evgeny Zaytsev and Philip Sawyer, have disclosed beneficial ownership of 6.5% of Coherus Oncology, Inc.'s common stock.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 6.6% beneficial ownership stake in Coherus BioSciences Inc. as of March 31, 2025.

Thomas A. Satterfield, Jr. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.2% of Coherus BioSciences, Inc.'s common stock as of April 14, 2025.

Rubric Capital Management LP and David Rosen have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.56% of Coherus BioSciences, Inc.'s common stock as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.6% beneficial ownership stake in Coherus BioSciences Inc. as of December 31, 2024.